AML
Conference Coverage
Myeloid patients respond robustly to Moderna COVID vaccine
Among 46 patients, nearly all seroconverted after second shot.
Conference Coverage
For leukemias, COVID-19 death risks tied to poor prognoses, ICU deferrals
COVID-19 death risks for acute leukemias were driven by poor physician-assessed prognoses and opting out of recommended ICU care.
Conference Coverage
Reduced-intensity transplant benefits older patients with AML
News
Predicting outcomes in therapy-related AML
News
Don’t delay: Cancer patients need both doses of COVID vaccine
For patients with cancer, immune response to the first dose of the Pfizer COVID-19 vaccine is reduced, and there is a need for a booster dose at...
Article
Sequential Targeted Treatment for a Geriatric Patient with Acute Myeloid Leukemia with Concurrent FLT3-TKD and IDH1 Mutations
Targeting and monitoring several acute myeloid leukemia mutations sequentially provides insights into optimal treatment plans.
Conference Coverage
Black race linked to poorer survival in AML
News
Beat AML: Precision medicine strategy feasible, superior to SOC for AML
"The study is changing significantly the way we look at treating patients with AML, showing that precision medicine ... can improve short- and...
Conference Coverage
Novel agents hold promise for frontline AML treatment
Conference Coverage
Survey quantifies COVID-19’s impact on oncology
Oncologists detail how COVID-19 has impacted care, caregivers, continuing medical education, and clinical trials.
